retatrutide weight loss per week Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% ADA 2026: Retatrutide Revolution

Its about democratizing access to metabolic care in a country with over 90 million diabetics

Start your journey to a healthier, more beautiful you today

We speak with one of the lead scientists who discovered this gut hormone on how these drugs actually work in our bodies.

IQVIA Payer Control Library The Bottom Line The GLP-1 market sits at the intersection of clinical innovation and patient behavior, where real-world persistence often falls short of therapeutic potential

but that does not mean they can ignore it

Now the largest study of its kind suggests it and other medications like ithave a host of other potential health benefits beyond obesity, but could also bring increased risk of other conditions.